Published in Eur J Cancer on December 01, 1999
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 3.38
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging (2008) 3.24
Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med (2009) 2.84
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging (2004) 2.58
¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging (2014) 2.21
Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging (2013) 2.10
Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging (2006) 2.08
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol (2009) 2.07
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood (2014) 1.95
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2011) 1.82
Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging (2007) 1.81
Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer (2008) 1.73
A gist of gastrointestinal stromal tumors: A review. World J Gastrointest Oncol (2013) 1.72
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res (2013) 1.60
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging (2011) 1.50
Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol (2005) 1.49
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. J Clin Oncol (2015) 1.49
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging (2004) 1.47
Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging (2006) 1.47
Variability in PET quantitation within a multicenter consortium. Med Phys (2010) 1.46
Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol (2009) 1.43
How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging (2006) 1.41
Positron Emission Tomography (PET) in Oncology. Cancers (Basel) (2014) 1.41
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2014) 1.38
PET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error. Transl Oncol (2009) 1.38
Dynamic PET denoising with HYPR processing. J Nucl Med (2010) 1.35
Quantitative techniques in 18FDG PET scanning in oncology. Br J Cancer (2008) 1.33
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2007) 1.33
FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med (2012) 1.32
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol (2008) 1.30
Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer (2010) 1.27
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 1.23
Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med (2012) 1.21
Molecular imaging in cancer treatment. Eur J Nucl Med Mol Imaging (2010) 1.21
18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging (2009) 1.20
How to study optimal timing of PET/CT for monitoring of cancer treatment. Am J Nucl Med Mol Imaging (2011) 1.19
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med (2013) 1.19
The role of PET in monitoring therapy. Cancer Imaging (2005) 1.17
Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging (2005) 1.17
Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World J Gastroenterol (2012) 1.15
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer (2012) 1.13
Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging (2007) 1.12
Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging (2003) 1.11
Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging (2009) 1.11
Summary report of the First International Workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany. Mol Imaging Biol (2013) 1.10
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer (2012) 1.09
Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. Eur J Nucl Med Mol Imaging (2015) 1.09
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol (2012) 1.08
Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol (2011) 1.07
18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol (2011) 1.07
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget (2014) 1.06
Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging (2012) 1.05
Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg (2005) 1.05
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol (2014) 1.04
(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging (2015) 1.04
Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother (2011) 1.04
SUVref: reducing reconstruction-dependent variation in PET SUV. EJNMMI Res (2011) 1.02
Design considerations for using PET as a response measure in single site and multicenter clinical trials. Acad Radiol (2011) 1.02
Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol (2013) 1.02
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2010) 1.01
CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur J Nucl Med Mol Imaging (2002) 1.01
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging (2011) 1.01
Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging (2004) 1.01
Molecular medicine successes in neuroscience. Mol Med (2008) 1.00
Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol (2011) 1.00
Quantitative radiomics: impact of stochastic effects on textural feature analysis implies the need for standards. J Med Imaging (Bellingham) (2015) 0.99
Imaging response to systemic therapy for bone metastases. Eur Radiol (2009) 0.99
Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging (2004) 0.99
Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys (2012) 0.99
Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging (2004) 0.99
Glucose metabolism measured by [¹⁸F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Transl Oncol (2011) 0.98
Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging (2014) 0.98
Clinical trial design for target specific anticancer agents. Invest New Drugs (2003) 0.98
18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. Skeletal Radiol (2011) 0.98
Methodology for quantitative rapid multi-tracer PET tumor characterizations. Theranostics (2013) 0.98
Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology (2016) 0.97
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2011) 0.97
State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology (2014) 0.97
The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging (2012) 0.97
Imaging of lung cancer in the era of molecular medicine. Acad Radiol (2011) 0.97
Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget (2014) 0.95
Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging (2013) 0.95
Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging (2008) 0.95
Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy. Eur J Nucl Med Mol Imaging (2012) 0.95
The clinical significance and management of lesion motion due to respiration during PET/CT scanning. Cancer Imaging (2011) 0.95
Correlation of PET/CT standardized uptake value measurements between dedicated workstations and a PACS-integrated workstation system. J Digit Imaging (2007) 0.94
Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging (2006) 0.94
Accuracy of MRI and 18F-FDG PET/CT for restaging after preoperative concurrent chemoradiotherapy for rectal cancer. World J Surg (2009) 0.93
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics (2010) 0.93
Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med (2000) 6.34
Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage (1997) 4.13
The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab (1990) 3.78
Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain (1990) 3.54
Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol (1986) 3.07
Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet (1984) 3.05
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
The colour centre in the cerebral cortex of man. Nature (1989) 2.69
How should we introduce clinical PET in the UK? The oncologists need to have a view. Clin Oncol (R Coll Radiol) (2004) 2.56
Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc Natl Acad Sci U S A (1987) 2.46
Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med (2000) 2.37
No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol (2001) 2.31
Simplified chromatographic separation of immunoglobulin M from G and its application to toxoplasma indirect immunofluorescence. J Clin Microbiol (1979) 2.22
Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and heart rate variability. Eur Heart J (1995) 2.21
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med (2001) 2.18
Expression of cloned hepatitis B virus DNA in human cell cultures. Proc Natl Acad Sci U S A (1980) 2.08
MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology (2004) 2.07
Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med (2000) 2.06
Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol (2004) 1.92
Regional cerebral blood flow during volitional breathing in man. J Physiol (1991) 1.84
Non-surgical management of early breast cancer in the United Kingdom: radiotherapy fractionation practices. Clinical Audit Sub-committee of the Faculty of Clinical Oncology, Royal College of Radiologists, and the Joint Council for Clinical Oncology. Clin Oncol (R Coll Radiol) (1995) 1.82
Correction for the presence of intravascular oxygen-15 in the steady-state technique for measuring regional oxygen extraction ratio in the brain: 1. Description of the method. J Cereb Blood Flow Metab (1983) 1.73
Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry (2005) 1.69
Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage (1998) 1.59
Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med (1991) 1.58
Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells. Eur J Biochem (1977) 1.57
Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med (1997) 1.55
Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology (2005) 1.54
Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab (1995) 1.54
Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med (2001) 1.52
The cost-effectiveness of wound management protocols of care. Br J Nurs (2000) 1.52
An assessment of clinically optimal gold marker length and diameter for pelvic radiotherapy verification using an amorphous silicon flat panel electronic portal imaging device. Br J Radiol (2005) 1.50
Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol (1996) 1.49
Changes in global cerebral blood flow in humans: effect on regional cerebral blood flow during a neural activation task. J Physiol (1993) 1.48
Coping style and depression influence the healing of diabetic foot ulcers: observational and mechanistic evidence. Diabetologia (2010) 1.47
Oesophageal endoscopic ultrasound with fine needle aspiration improves and simplifies the staging of lung cancer. Thorax (2004) 1.47
Staphylococcal IgE antibodies, hyperimmunoglobulinemia E and Staphylococcus aureus infections. N Engl J Med (1979) 1.47
Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med (1991) 1.46
Dipyridamole-induced increased glucose uptake in patients with single-vessel coronary artery disease assessed with PET. J Nucl Cardiol (2001) 1.45
Cerebral perfusion and metabolism in resuscitated patients with severe post-hypoxic encephalopathy. J Neurol Sci (2003) 1.44
Carbon-11 acetate as a tracer of myocardial oxygen consumption. Eur J Nucl Med (2001) 1.44
Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol (2001) 1.42
Influence of dietary protein restriction on immune competence. II. Effect on lymphoid tissue. Clin Exp Immunol (1976) 1.40
Performance of a randomization test for single-subject (15)O-water PET activation studies. J Cereb Blood Flow Metab (1997) 1.40
Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med (2007) 1.40
Recognizing the feet as being at risk from pressure damage. Br J Nurs (2002) 1.38
Dipyridamole vasodilator response after human orthotopic heart transplantation: quantification by oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol (1992) 1.38
Evaluation of quality of contents of general practice records. Br Med J (Clin Res Ed) (1984) 1.38
HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med (1994) 1.38
Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med (2001) 1.36
Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med (1998) 1.36
Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology (2009) 1.35
11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol (2003) 1.34
Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res (1992) 1.33
Normal and pathological aging--findings of positron-emission-tomography. J Neural Transm (Vienna) (1998) 1.33
Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Am J Cardiol (1996) 1.33
Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab (1992) 1.31
Image-derived input functions for determination of MRGlu in cardiac (18)F-FDG PET scans. J Nucl Med (2001) 1.30
Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med (1995) 1.30
F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology (1994) 1.27
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Identification of protein-binding sites in the hepatitis B virus enhancer and core promoter domains. Mol Cell Biol (1988) 1.26
Parametric image reconstruction using spectral analysis of PET projection data. Phys Med Biol (1998) 1.26
Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med (2002) 1.26
Brain plasticity in poststroke aphasia: what is the contribution of the right hemisphere? Brain Lang (1998) 1.24
The role of D-1 and D-2 receptors. Nature (1980) 1.24
The toxicity of inactivated bacteria and endotoxin in mice suffering from protein malnutrition. J Reticuloendothel Soc (1975) 1.23
Correction for the presence of intravascular oxygen-15 in the steady-state technique for measuring regional oxygen extraction ratio in the brain: 2. Results in normal subjects and brain tumour and stroke patients. J Cereb Blood Flow Metab (1983) 1.22
Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation (1997) 1.22
Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia (1994) 1.22
Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med (2003) 1.21
Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology (2008) 1.21
64Cu metabolism in Menkes and normal cultured skin fibroblasts. Pediatr Res (1978) 1.21
Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse (1992) 1.20
Radionuclide imaging of the painful hip arthroplasty: positron-emission tomography versus triple-phase bone scanning. J Bone Joint Surg Br (2005) 1.19
Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer (1988) 1.19
Changes in brain metabolism associated with remission in unipolar major depression. Acta Psychiatr Scand (2004) 1.18
Detection of unknown occult primary tumors using positron emission tomography. Cancer (1998) 1.18
Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI). Dement Geriatr Cogn Disord (2009) 1.18
Plasticity of language networks in patients with brain tumors: a positron emission tomography activation study. Ann Neurol (2001) 1.17
Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. Circulation (1991) 1.15
Drug quantitation on a benchtop liquid chromatography-tandem mass spectrometry system. J Chromatogr A (1997) 1.15
Disturbance and recovery of language function: correlates in PET activation studies. Neuroimage (2003) 1.15
The direct calculation of parametric images from dynamic PET data using maximum-likelihood iterative reconstruction. Phys Med Biol (1997) 1.14
Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med (2008) 1.12
Inhibition of dimethyl sulfoxide-stimulated Friend cell erythrodifferentiation by hydrocortisone and other steroids. Proc Natl Acad Sci U S A (1978) 1.11
(R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol (2003) 1.11
Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med (1996) 1.11
CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease. Eur J Neurol (2008) 1.10
Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management. J Wound Care (2010) 1.09
Common HLA-B8-DR3 haplotype in Northern India is different from that found in Europe. Tissue Antigens (2002) 1.09
Species composition and seasonal abundance of stink bugs (Hemiptera: Pentatomidae) in Louisiana soybean. Environ Entomol (2013) 1.09
Vascular dementia: perfusional and metabolic disturbances and effects of therapy. J Neural Transm Suppl (1996) 1.09
Measurement of regional cerebral blood flow and oxygen utilisation in patients with cerebral tumours using 15O and positron emission tomography: analytical techniques and preliminary results. Neuroradiology (1982) 1.09
Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography. J Nucl Med (1992) 1.08
The response of protein-deficient mice to tetanus toxoid. Effects of antigen dose, adjuvants, period of deprivation and age on antibody production. Immunology (1977) 1.08
Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin (1999) 1.08
Recommended distributions for exposure factors frequently used in health risk assessment. Risk Anal (1994) 1.08
An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med (1994) 1.08